PMID- 35728747
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20220901
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 248
DP  - 2022 Aug
TI  - Interstitial lung disease progression in patients with anti-aminoacyl 
      transfer-RNA-synthetase autoantibodies is characterized by higher levels of 
      sCD163.
PG  - 56-61
LID - S0165-2478(22)00094-3 [pii]
LID - 10.1016/j.imlet.2022.06.007 [doi]
AB  - Patients with anti-tRNA autoantibodies are characterized by arthritis, mechanic s 
      hands, fever, Raynaud s phenomenon, and interstitial lung disease (ILD), in at 
      least two clinical scenarios: the antisynthetase syndrome (ASSD) and interstitial 
      pneumonia with autoimmune features (IPAF). The anti-tRNA-ILD treatment is 
      centered on the administration of corticosteroids and a wide variety of 
      immunosuppressive drugs; however, the effectiveness of the treatment depends on 
      factors not fully understood. This research work aimed to quantify the serum 
      levels of two molecules related to pulmonary fibrosis and explore their 
      relationship with the progression of ILD associated with ASSD METHODOLOGY: Serum 
      levels of sCD163 and TGF-beta1 from baseline and after six months of treatment of 
      ILD patients' positives to anti-tRNA were included in the current study. At six 
      months, patients were classified as with or without ILD progression RESULTS: 
      Forty patients were included (anti-Jo1, anti-PL7, anti-PL12, and anti-Ej). Five 
      patients (12.5%) had ILD progression and were characterized by higher levels of 
      sCD163 at baseline. Baseline sCD163 serum levels showed good discriminatory 
      capacity in patients with ILD progression. On the other hand, at follow-up, serum 
      TGF-beta1 levels significantly increased in both patients' groups, with and without 
      progression CONCLUSION: Basal levels of sCD163 were higher in patients who later 
      developed ILD progression and kinetics of both molecules suggests the 
      participation of M2 macrophages in the development of ILD.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Ramos-Martinez, Espiridion
AU  - Ramos-Martinez E
AD  - Experimental Medicine Research Unit, Facultad de Medicina, Universidad Nacional 
      Autonoma de Mexico 06720 Mexico City Mexico.
FAU - Falfan-Valencia, Ramces
AU  - Falfan-Valencia R
AD  - HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio 
      Villegas, Mexico City 14080, Mexico.
FAU - Perez-Rubio, Gloria
AU  - Perez-Rubio G
AD  - HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio 
      Villegas, Mexico City 14080, Mexico.
FAU - Mejia, Mayra
AU  - Mejia M
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias Ismael Cosio Villegas, Ismael Cosio Villegas, Calz. 
      Tlalpan 4502, Seccion XVI, Tlalpan, Mexico City, Ciudad de Mexico 14080, Mexico.
FAU - Mejia-Hurtado, Jose Guillermo
AU  - Mejia-Hurtado JG
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias Ismael Cosio Villegas, Ismael Cosio Villegas, Calz. 
      Tlalpan 4502, Seccion XVI, Tlalpan, Mexico City, Ciudad de Mexico 14080, Mexico.
FAU - Buendia-Roldan, Ivette
AU  - Buendia-Roldan I
AD  - Translational Research Laboratory on Aging and Pulmonary Fibrosis, Instituto 
      Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, 
      Mexico.
FAU - Gonzalez-Perez, Montserrat I
AU  - Gonzalez-Perez MI
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias Ismael Cosio Villegas, Ismael Cosio Villegas, Calz. 
      Tlalpan 4502, Seccion XVI, Tlalpan, Mexico City, Ciudad de Mexico 14080, Mexico.
FAU - Mateos-Toledo, Heidegger N
AU  - Mateos-Toledo HN
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias Ismael Cosio Villegas, Ismael Cosio Villegas, Calz. 
      Tlalpan 4502, Seccion XVI, Tlalpan, Mexico City, Ciudad de Mexico 14080, Mexico.
FAU - Rojas-Serrano, Jorge
AU  - Rojas-Serrano J
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias Ismael Cosio Villegas, Ismael Cosio Villegas, Calz. 
      Tlalpan 4502, Seccion XVI, Tlalpan, Mexico City, Ciudad de Mexico 14080, Mexico; 
      Profesor, Programa de Maestria y Doctorado en Ciencias Medicas, Facultad de 
      Medicina, Universidad Nacional Autonoma de Mexico, Mexico City 14080, Mexico. 
      Electronic address: jrojas@iner.gob.mx.
LA  - eng
PT  - Journal Article
DEP - 20220618
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Autoantibodies)
RN  - 0 (CD163 antigen)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 63231-63-0 (RNA)
RN  - EC 6.1.1.- (Amino Acyl-tRNA Synthetases)
RN  - Antisynthetase syndrome
SB  - IM
MH  - *Amino Acyl-tRNA Synthetases
MH  - Antigens, CD/*blood
MH  - Antigens, Differentiation, Myelomonocytic/*blood
MH  - Autoantibodies
MH  - Disease Progression
MH  - Humans
MH  - *Lung Diseases, Interstitial/drug therapy
MH  - Myositis
MH  - RNA
MH  - Receptors, Cell Surface/*blood
MH  - Transforming Growth Factor beta1
OTO - NOTNLM
OT  - Antisynthetase syndrome
OT  - Interstitial lung disease
OT  - TGF-beta1
OT  - sCD163
EDAT- 2022/06/22 06:00
MHDA- 2022/08/12 06:00
CRDT- 2022/06/21 19:25
PHST- 2021/12/02 00:00 [received]
PHST- 2022/04/22 00:00 [revised]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/06/22 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
PHST- 2022/06/21 19:25 [entrez]
AID - S0165-2478(22)00094-3 [pii]
AID - 10.1016/j.imlet.2022.06.007 [doi]
PST - ppublish
SO  - Immunol Lett. 2022 Aug;248:56-61. doi: 10.1016/j.imlet.2022.06.007. Epub 2022 Jun 
      18.